TORONTO, ONTARIO--(Marketwire - September 09, 2008) - Lorus Therapeutics Inc, (TSX: LOR)(AMEX: LRP) ("Lorus"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced a scientific publication by a clinical research team at The Ohio State University (OSU) College of Pharmacy entitled "Enzyme Kinetics of GTI-2040, a Phosphorothioate Oligonucleotide Targeting Ribonucleotide Reductase" (Drug Metabolism and Disposition 2008, July 24 Epub ahead of print).
